Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
1.110
-0.040 (-3.48%)
At close: Feb 21, 2025, 4:00 PM
1.120
+0.010 (0.91%)
After-hours: Feb 21, 2025, 4:13 PM EST
Biofrontera Employees
As of December 31, 2023, Biofrontera had 85 total employees, including 83 full-time and 2 part-time employees. The number of employees increased by 4 or 4.94% compared to the previous year.
Employees
85
Change (1Y)
4
Growth (1Y)
4.94%
Revenue / Employee
$415,976
Profits / Employee
-$151,024
Market Cap
8.60M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 85 | 4 | 4.94% |
| Dec 31, 2022 | 81 | 12 | 17.39% |
| Dec 31, 2021 | 69 | 13 | 23.21% |
| Dec 31, 2020 | 56 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
BFRI News
- 6 weeks ago - Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - GlobeNewsWire
- 2 months ago - Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market - GlobeNewsWire
- 2 months ago - Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference - Accesswire
- 3 months ago - Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note - GlobeNewsWire
- 3 months ago - Biofrontera Inc. (BFRI) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 - Accesswire
- 4 months ago - Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - GlobeNewsWire